Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Beam Therapeutics Inc shares valued at $220,045 were sold by Cavanagh Bethany J on Feb 18 ’25. At $35.00 per share, Cavanagh Bethany J sold 6,287 shares. The insider’s holdings dropped to 37,527 shares worth approximately $0.94 million following the completion of this transaction.
Also, Bellon Christine sold 10,000 shares, netting a total of over 340,000 in proceeds. Following the sale of shares at $34.00 each, the insider now holds 102,968 shares.
Before that, CHRISTINE BELLON had added 10,000 shares to its account. In a trade valued at $340,000, the Officer bought Beam Therapeutics Inc shares for $34.00 each.
As published in a research note from Scotiabank on March 10, 2025, Beam Therapeutics Inc [BEAM] has been rated up from a Sector perform to a Sector outperform and the price target has been revised to $40. Analysts at Cantor Fitzgerald upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in late January. As of November 06, 2024, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for BEAM. Earlier on October 16, 2024, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for BEAM stock.
Analyzing BEAM Stock Performance
During the last five days, there has been a drop of approximately -8.04%. Over the course of the year, Beam Therapeutics Inc shares have jumped approximately 1.05%. Shares of the company reached a 52-week high of $35.25 on 02/18/25 and a 52-week low of $22.50 on 01/15/25. A 50-day SMA is recorded $26.95, while a 200-day SMA reached $25.82.
Support And Resistance Levels for Beam Therapeutics Inc (BEAM)
According to the 24-hour chart, there is a support level at 23.73, which, if violated, would cause prices to drop to 22.39. In the upper region, resistance lies at 27.37. The next price resistance is at 29.67. RSI (Relative Strength Index) is 42.43 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.84, which suggests the price will decrease in the coming days. Percent R is at 84.25%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Beam Therapeutics Inc (BEAM)?
On July 23, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $80.
